Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

Go back to Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
(NASDAQ: DFTX) Delayed: 38.09 +0.09 (0.24%)
Previous Close $38.00    52 Week High
Open $37.94    52 Week Low
Day High $38.54    P/E N/A 
Day Low $37.38    EPS
Volume 1,128,929